Unilife Corporation (NASDAQ: UNIS) is a developer and commercial supplier of injectable drug delivery systems. UNIS has a portfolio of innovative, differentiated products with a primary focus on wearable injectors. UNIS shares fell to $2.64 on May 24, 2016 but have rebounded to over $4 per share. The company has been beseeched by several law firms seeking class action shareholder lawsuits. The report that follows will update you completely about UNIS- Read More
 
The acquisition of BioD, LLC, a private company, has been announced by Derma Sciences Inc. (NASDAQ: DSCI) a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of which result from diabetes and poor vascular functioning. The report that follows will give you details of the transaction and describes the synergies created by the combination- Read More
 
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. EVOK shares tumbled 85% earlier this month when the company’s Phase III clinical trial of EVK-001 failed to achieve its primary endpoint of symptom improvement at the end of four weeks in female patients with symptomatic diabetic gastroparesis. Find out if this is the end for EVOK and EVK-001 when you read this article- Read More
 
 
 
DISCLAIMER
 
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.
 
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. The subject Companies have not compensated Traders News Source for the creation or dissemination of this report. Traders News Source is the party responsible for issuing this report/release and for hosting the full report on Traders News Source website.
 
NOT FINANCIAL ADVICE
Traders News Source makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
 
NO WARRANTY OR LIABILITY ASSUMED
Traders News Source is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Traders News Source whatsoever for any direct, indirect or consequential loss arising from the use of this document. Traders News Source expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Traders News Source does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
 Traders News Source produces reports, articles, blogs, and investment newsletters covering companies listed on NYSE and NASDAQ exchanges. Traders News Source has two distinct and independent operating segments. One produces non-compensated analyst and or expert certified content generally in the form of press releases, articles and reports. The other produces compensated content, which typically consists of compensated investment newsletters, articles and reports.
 
HIGH DEGREE OF RISK
 
There is an extremely high inherent risk when investing in micro and small cap biotech securities that
have little to no revenue and are dependent upon an approval from the development of their drug
pipeline. You could lose your entire investment.
 
Source: Traders News Source
Contact: editor@tradersnewssource.com